Adverum Biotechnologies (Avalanche)

^{Priced, Nasdaq: ADVM}

Early-stage biotech developing a gene therapy for wet AMD.

Industry: Health Care

First Day Return: +64.6%

ADVM

Early-stage biotech developing a gene therapy for wet AMD.

IPO News for Adverum Biotechnologies (Avalanche)

It's electric: Spark Therapeutics increases proposed IPO deal size by 48% to $130 million 01/28/15
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price 08/01/14
IPO market brought down by biotech wreck and market sell off 07/31/14

IPO Data
IPO Date	07/30/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$102
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.avalanchebiotech.com
Headquarters	Menlo Park, CA, United States
Founded	2006
Employees at IPO	14

IPO News for Adverum Biotechnologies (Avalanche)

Adverum Biotechnologies (Avalanche) (ADVM) Performance